Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ENLV | 6-K | bearish | 8/10 | Enlivex announced a $400M private placement of ordinary shares at a premium to market price, with proceeds intended to f | Jul 28, 2026 |
| PHGE | PRESS-RELEASE | bearish | 7/10 | BiomX amended a $1.25M promissory note with Water.IO, extending maturity to November 1, 2026, and issuing 800,000 restri | Jul 28, 2026 |
| PHGE | 8-K | bearish | 8/10 | BiomX Inc. amended a $1.25M promissory note with Water IO Ltd., extending the maturity from July 10, 2026 to November 1, | Jul 28, 2026 |
| PVLA | PRESS-RELEASE | neutral | 1/10 | Palvella Therapeutics Inc. announced it will host a conference call on August 4, 2026 to discuss its Q2 2026 results. | Jul 28, 2026 |
| HBIO | PRESS-RELEASE | neutral | 1/10 | Harvard Bioscience, Inc. announced it will host a conference call on August 11, 2026 to discuss its Q2 2026 results. | Jul 28, 2026 |
| KNSA | PRESS-RELEASE | bullish | 7/10 | Kiniksa reported Q2 2026 ARCALYST net product revenue of $243.6M (~55% YoY growth), beating consensus estimates of $226. | Jul 28, 2026 |
| RGEN | 8-K | bullish | 7/10 | Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company | Jul 28, 2026 |
| KNSA | 8-K | bullish | 7/10 | Kiniksa reported Q2 2026 ARCALYST net product revenue of $243.6M (~55% YoY growth), beating consensus estimates of $226. | Jul 28, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced completion of treatment for all 24 participants in Part A of its Phase I/II trial for CMND- | Jul 28, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | CEO Robert Blum exercised 7,500 options at $10.60 and immediately sold the shares at $80.87 for $607K in proceeds, while | Jul 28, 2026 |
| CDXS | 8-K | bearish | 6/10 | Codexis closed a public offering of 16,666,667 shares of common stock at $1.50 per share, raising approximately $23.1 mi | Jul 27, 2026 |
| RAJAF | 6-K | neutral | 2/10 | TFA Therapeutics, Inc. (f/k/a Cordyceps Sunshine Biotech Holdings Co., Ltd.) filed a 6-K reporting a corporate name chan | Jul 27, 2026 |
| NUVL | 15-12G | neutral | 3/10 | Nuvalent filed a Form 15-12G to terminate its SEC registration under Section 12(g) following the completion of GSK plc's | Jul 27, 2026 |
| VRXA | 6-K | neutral | 3/10 | Veraxa Biotech announced the advancement of its bispecific ADC program VXA-222 into the next collaboration phase with Om | Jul 27, 2026 |
| APVO | 8-K | neutral | 4/10 | Aptevo Therapeutics announced a new solid tumor strategy and filed a patent application for a proprietary Nectin-4 x PD- | Jul 27, 2026 |
| FOXO | 8-K | bullish | 5/10 | FOXO Technologies' subsidiary Vector BioSource has entered into a definitive asset purchase agreement to acquire four U. | Jul 27, 2026 |
| OPK | 8-K | mixed | 5/10 | OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share | Jul 27, 2026 |
| MEDP | 144 | bearish | 5/10 | Chairman August J. Troendle filed a Form 144 notice of intent to sell 307,959 shares of Medpace common stock, valued at | Jul 27, 2026 |
| INCY | CLUSTER | neutral | 3/10 | Two senior INCY executives (CMO and EVP of U.S. Commercial) sold a combined $341K of stock on July 16, 2026, while two o | Jul 27, 2026 |
| CGON | PRESS-RELEASE | bullish | 7/10 | CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncol | Jul 27, 2026 |
| XOMA | 15-12G | bearish | 7/10 | XOMA Royalty Corp filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 27, 2026. Th | Jul 27, 2026 |
| PHGE | 424B5 | bearish | 7/10 | BiomX Inc. filed a prospectus supplement to its existing ATM offering agreement with H.C. Wainwright, updating the maxim | Jul 27, 2026 |
| DNLI | PRESS-RELEASE | neutral | 1/10 | Denali Therapeutics Inc. announced it will report its Q2 2026 results on August 6, 2026. | Jul 27, 2026 |
| ORGO | PRESS-RELEASE | bullish | 6/10 | Organogenesis published peer-reviewed RCT results showing Affinity plus standard of care significantly improved wound cl | Jul 27, 2026 |
| PFE | COURT-RULING | neutral | 1/10 | The court issued an order to show cause in Steele v. Pfizer Inc, a pro se lawsuit, after the plaintiff failed to file an | Jul 27, 2026 |
| RADX | 6-K | bearish | 6/10 | Radiopharm Theranostics announced a multi-tranche capital raise: a US$4.1M registered direct offering of 1,281,646 ADSs | Jul 27, 2026 |
| SNY | 6-K | bearish | 5/10 | Sanofi reported two items in this 6-K: (1) a reorganization of its Executive Committee effective September 1, 2026, and | Jul 27, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced positive Phase III results for its wholly owned ADC, Sone-Ve (sonesitatug vedotin), demonstrating | Jul 27, 2026 |
| OKYO | 6-K | neutral | 2/10 | OKYO Pharma filed a 6-K announcing its participation in the BTIG Biotechnology Conference 2026, a virtual event on July | Jul 27, 2026 |
| CAMP | 8-K | mixed | 6/10 | Camp4 Therapeutics received Australian regulatory clearance to initiate a Phase 1/2 trial of CMP-002 for SYNGAP1-related | Jul 27, 2026 |